Antibiotic-resistant Pseudomonas aeruginosa: Focus on care in patients receiving assisted ventilation

Future Microbiology

Volumn 9, Issue 4, 2014, Pages 465-474

  Bassetti, Matteo ^a   Villa, Giovanni ^a   Pecori, Davide ^a  

^a S Maria Hospital   (Italy)

Author keywords

aerosolized antibiotics; amikacin; colistin; combination therapy; meropenem; multidrug resistant; piperacillin tazobactam; Pseudomonas aeruginosa; treatment; ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ASSISTED VENTILATION; HUMAN; MONOTHERAPY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA; ARTIFICIAL VENTILATION; DRUG COMBINATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; MICROBIOLOGY; PNEUMONIA, VENTILATOR-ASSOCIATED; PROCEDURES; PSEUDOMONAS INFECTIONS;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GUIDELINES AS TOPIC; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATION, ARTIFICIAL;

EID: 84900344311     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.7     Document Type: Review

References (36)

1. Kollef MH, Shorr A, Tabak YP et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture positive pneumonia. Chest 128(6), 3854-3862 (2005).
2. Niederman MS, Craven DE, Bonten MJ et al. American Thoracic Society and the Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171, 388-416 (2005).
3. Masterton RG, Gaooloway A, French G et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J. Antimicrob. Chemother. 62, 5-32 (2008).
4. Rotstein C, Evans G, Born A et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can. J. Infect. Dis. Med. Microbiol. 19, 19-53 (2008).
5. Koulenti D, Lisboa T, Brun-Buisson C et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit. Care Med. 37(8), 2360-2368 (2009).
6. Gastmeier P, Sohr D, Geffers C et al. Early- and late-onset pneumonia: is this still a useful classification? Antimicrob. Agents Chemother. 53(7), 2714-2718 (2009).
7. Kollef MH, Morrow LE, Niederman MS et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 129, 1210-1218 (2006).
8. Restrepo MI, Peterson J, Fernandez JF et al. Comparison of the bacterial etiology of early-onset and late-onset ventilator-associated pneumonia in subjects enrolled in 2 large clinical studies. Respir. Care 58(7), 1220-1225 (2013).
9. Martin-Loeches I, Deja M, Koulenti D et al. Potentially resistant microorganismsin intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med. 39, 672-681(2013).
10. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290(19), 2588-2598 (2003).
11. Hauser A, Cobb E, Bodi M et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med. 30, 521-528 (2002).
12. El Solh AA, Akinnusi ME, Wiener-Kronish JP et al. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 178, 513-519 (2008).
13. Song Y, Baer M, Srinivasan R et al. PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur. J. Clin. Microbiol. Infect. Dis. 31, 1837-1845 (2012).
14. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268-281 (2012).
15. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann. Intern. Med. 134(4), 298-314 (2001).
16. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am. J. Infect. Control 27(6), 520-532 (1999).
17. Gales AC, Jones RN, Turnidge J et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2), S146-S155 (2001).
18. Obritsch MD, Fish DN, MacLaren R et al. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother. 48(12), 4606-4610 (2004).
19. Sievert DM, Ricks P, Edwards JR et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34(1), 1-14 (2013).
20. Bod M, Garnacho J. Pseudomonas aeruginosa: combined treatment vs. monotherapy. Med. Intensiva 31(2), 83-87 (2007).
21. Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 27(Suppl. 2), S24-S28, 1999
22. Wu YL, Scott EM, Po AL et al. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 44(3), 389-392 (1999).
23. Lister PD, Wolter DJ, Wickman PA et al. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs. J. Antimicrob. Chemother. 57(5), 999-1003 (2006).
24. Pohlman JK, Knapp CC, Ludwig MD et al. Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against Gram-negative bacilli. Diagn. Microbiol. Infect. Dis. 26(1), 29-33 (1996).
25. Garnacho-Montero J, Sa-Borges M, Sole-Violan J et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicentre study comparing monotherapy with combination antibiotic therapy. Crit. Care Med. 35(8), 1888-1895 (2007).
26. Luna CM, Vujacich P, Niederman MS et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111, 676-685 (1997).
27. Pena C, Gomez-Zorrilla S, Oriol I et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur. J. Clin. Microb. Infect. Dis. 32(3), 413-420 (2013).
28. Aarts MA, Hancock JN, Heyland D et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit. Care Med. 36(1), 108-117 (2008).
29. Vardakas KZ, Tansarli GS, Bliziotis IA et al. Beta-lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int. J. Antimicrob. Agents 41(4), 301-310 (2013).
30. Bassetti M, Paiva JA, Masterton RG. The case for de-escalation in antimicrobial therapy: time to change our strategy in the management of septic shock? Intensive Care Med. 40(2), 284-285 (2014).
31. Planquette B, Timsit JF, Misset B et al. Pseudomonas aeruginosa ventilator-associated pneumonia: predictive factors of treatment failure. Am. J. Respir. Crit. Care Med. 188(1), 69-76 (2013).
32. Paul M, Bishara J, Levcovich A et al. Effectiveness and safety of colistin: prospective comparative cohort study. J. Antimicrob. Chemother. 65, 1019-1027 (2010).
33. Arnold HM, Sawyer AM, Kollef MH. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia. Respir. Care 57(8), 1226-1233 (2012).
34. Aoki N, Tateda K, Kikuchi Y et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J. Antimicrob. Chemother. 65, 534-542 (2009).
35. Lu Q, Girardi C, Zhang M et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 36, 1147-1155 (2010).
36. Luyt CE, Clavel M, Guntupalli K et al. Pharmacokinetics and lung delivery of PDDS-aerosolize damikacin (NKTR-061) in intubated and mechanically ventilated patientswith nosocomial pneumonia. Crit. Care 13(6), R200 (2009).